Sign In
Buy ULTI
$14.93
-0.470 (-3.05%)
At Close: Jun 03, 2026
Head to Head Comparison: REX IncomeMax Option Strategy ETF (NASDAQ:ULTI) and Shopify (NASDAQ:SHOP)
02:16am, Monday, 27'th Apr 2026
REX IncomeMax Option Strategy ETF (NASDAQ: ULTI - Get Free Report) and Shopify (NASDAQ: SHOP - Get Free Report) are both computer and technology companies, but which is the superior investment? We wil
Reviewing Shopify (NASDAQ:SHOP) and REX IncomeMax Option Strategy ETF (NASDAQ:ULTI)
01:28am, Monday, 27'th Apr 2026
Shopify (NASDAQ: SHOP - Get Free Report) and REX IncomeMax Option Strategy ETF (NASDAQ: ULTI - Get Free Report) are both computer and technology companies, but which is the superior stock? We will con
What's Driving CoreWeave (CRWV) Stock Higher Today?
11:05am, Thursday, 15'th Jan 2026
CoreWeave shares are up Thursday morning following a strong rebuttal from the company's CEO regarding the company's financing strategy.
CoreWeave (CRWV) Shares Pull Back Tuesday: What Investors Are Watching
02:19pm, Tuesday, 13'th Jan 2026
CoreWeave shares are down on Tuesday, pulling back following Monday's strength, as the company's CEO, Michael Intrator, dismissed allegations of "circular financing" with Nvidia.
CoreWeave (CRWV) Soars As CEO Dismisses Nvidia 'Circular Financing' Allegations
12:22pm, Monday, 12'th Jan 2026
CoreWeave shares are up on Monday after CEO Michael Intrator rejected allegations of "circular financing" with Nvidia.
ULTY, Meet ULTI, Your Newest Competitor
02:01am, Friday, 19'th Dec 2025
YieldMax Ultra Option Income Strategy ETF has underperformed, with a significant price decline since July and negative total returns versus the market. REX SHARES launched the REX IncomeMax Option Str
REX Shares Appoints Matt Holcomb as Portfolio Manager for REX IncomeMax™ Option Strategy ETF (Ticker: ULTI)
08:00am, Monday, 03'rd Nov 2025
NEW YORK--(BUSINESS WIRE)--REX Shares (“REX”), a leading innovator in alternative exchange-traded funds (ETFs), is pleased to announce the appointment of Matt Holcomb as Portfolio Manager for the
REX Shares Launches REX IncomeMax Option Strategy ETF (Ticker: ULTI)
08:00am, Friday, 31'st Oct 2025
MIAMI--(BUSINESS WIRE)--REX Shares (“REX”), a leading innovator in alternative ETFs, today announced the launch of the REX IncomeMax Option Strategy ETF (Ticker: ULTI), an actively managed fund de
Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology
11:47am, Tuesday, 11'th May 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #ClinicalTrials--Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in
Ultimovacs ASA: First Quarter 2021 Result Presentation
02:05am, Tuesday, 11'th May 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #1Q21--Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2021 re
Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings
11:05am, Monday, 10'th May 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #ASCO--Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its management team wil
Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting
10:03am, Wednesday, 28'th Apr 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI--Ultimovacs ASA ("Ultimovacs", ticker ULTI) today announced that an abstract on the Company's Phase I trial evaluating its universal cancer vaccine, UV1, in com
Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021
08:35am, Saturday, 10'th Apr 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #AACR2021--Ultimovacs ASA ("Ultimovacs", ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinic
OSLO, Norway--(BUSINESS WIRE)---- $ULTI--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical e
Ultimovacs ASA: Fourth Quarter 2020 Result Presentation
02:05am, Wednesday, 17'th Feb 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #4Q20--Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its fourth quarter 2021 r
